Search Results
Results found for "Domain Therapeutics"
- Novo Nordisk moves to strengthen obesity efforts
Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics
- Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
It’s about revealing therapeutic liabilities before they derail development. constitutive activity play in uncovering inverse agonists , and how can you exploit this phenomenon for novel therapeutic
- 📰 GPCR Weekly News, February 20 to 26, 2023
Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics
- 📰 GPCR Weekly News, May 6 to 12, 2024
Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic neutrophil biology: inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic
- Applications of Cryo-EM in small molecule and biologics drug design
As a result, cryo-EM has begun to make major impacts in bringing critical therapeutics to market. In this review, we discuss recent instructive examples of impacts from cryo-EM in therapeutics design
- Dr. Josephine (Pina) Cardarelli - Dr. GPCR Podcast
Pina Cardarelli, CSO of GPCR Therapeutics.
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
From omics to epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics
- Targeting the M1 muscarinic receptor in neurodegenerative disease
the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
prediction of first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic
- Molecular insights into psychedelic drug action
actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic
- Molecular targets of psychedelic-induced plasticity
toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic
- Dr. Juan José Fung - Dr. GPCR Podcast
Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
– CXCR4 oligomer disruption boosts therapeutic response in lymphoid neoplasms Dr.
- Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild trauma
This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model
- G protein-coupled receptor signaling: transducers and effectors
physiological functions and in a large number of Food and Drug Administration (FDA)-approved drugs as therapeutic
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
combination of Steyaert’s fundamental research and his ability to apply the research to the development of therapeutic
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
PAMs assumed therapeutically viable without verifying whether they amplify affinity or efficacy. Lower-affinity alternatives may produce deeper, more therapeutically relevant coverage.
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
These advances have paved the way for development of novel ligands for different therapeutic applications
- From DNA day to GPCR genomics
GPCR-targeted drugs, and the exploration of GPCRs as key regulators of physiological processes and therapeutic analysis, have facilitated drug discovery and design targeting GPCRs, leading to the development of novel therapeutics
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover SMILES-based de novo molecular generation with curriculum and deep reinforcement learning Structure Therapeutics
- 📰 GPCR Weekly News, May 22 to 28, 2023
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- Viral G Protein-Coupled Receptors Encoded by β- and γ-Herpesviruses
Finally, we briefly discuss the therapeutic targeting of vGPCRs as future treatment of acute and chronic
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
These nuances define therapeutic potential and side-effect risk. Each mode reshapes both potency and therapeutic window.
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic









